1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Arena's lorcaserin a year out from next FDA review

 
• By Donna Young

Arena Pharmaceuticals and commercialization partner Eisai said it could be a year before they resubmit their marketing application to the US FDA for their embattled weight-loss drug lorcaserin, citing the need to complete additional animal studies and a small 10-patient volunteer trial after regulators rejected the drug on concerns that rat data showed an increase in tumours.

Arena Pharmaceuticals and commercialization partner Eisai said it could be a year before they resubmit their marketing application to the US FDA for their embattled weight-loss drug lorcaserin, citing the need to complete additional animal studies and a small 10-patient volunteer trial after regulators rejected the drug on concerns that rat data showed an increase in tumours.

The companies said it likely would be mid-2012 before the FDA makes another approval decision on the drug, which received...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.